GLP-1

Danuglipron: Pfizer's Oral GLP-1 Pill — Complete 2026 Guide

Medici

30 Apr 2026 — 7 min read

For a moment in 2023 and 2024, Pfizer's danuglipron looked like it might democratize the GLP-1 revolution. An oral pill — no injections, no refrigeration, no weekly shot schedules — that could help millions lose significant weight. Then, in April 2025, Pfizer pulled the plug. One patient. One liver injury signal. The entire program halted.

If you've been following the race for an oral GLP-1 weight loss pill, danuglipron's story is essential reading. This guide covers everything: how the drug worked, what the Phase 2b data actually showed, why the tolerability profile was always a concern, and what danuglipron's discontinuation means for the broader oral GLP-1 landscape heading into 2026.

What Is Danuglipron?

Danuglipron (also known by its research code PF-06882961) is a small-molecule, oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Pfizer. Unlike injectable GLP-1 drugs such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), danuglipron is a non-peptide, chemically synthesized compound that can be taken as a conventional pill — no special formulation tricks or food-timing restrictions required.

Pfizer's scientists identified danuglipron through a sensitized high-throughput screening process targeting the GLP-1 receptor. The compound belongs to a class of fluoropyrimidine-based molecules optimized to activate the GLP-1 receptor with nanomolar potency. It was initially investigated for type 2 diabetes, then pivoted toward obesity and chronic weight management, which became its primary clinical focus.

How Danuglipron Works: A Novel Binding Mechanism

To understand what made danuglipron scientifically interesting, you need to understand how it differs from the peptide-based GLP-1 drugs that dominate the market today.

Semaglutide and liraglutide are peptide molecules — large biological structures that mimic the natural GLP-1 hormone. They bind to the extracellular domain of the GLP-1 receptor in a way that closely mirrors the natural hormone. Because peptides degrade rapidly in the digestive tract, injectable delivery has historically been necessary (or, in oral semaglutide's case, requires special absorption enhancers and strict fasting protocols).

Danuglipron, by contrast, is a small molecule. Its binding mechanism is fundamentally different: it interacts at the Trp33 region of the receptor's extracellular domain through van der Waals interactions and hydrogen bonding with both extracellular loop 1 (ECL1) and extracellular loop 2 (ECL2). Peptide-based GLP-1 agonists only interact with ECL2. This distinct binding mode is what allows danuglipron to be orally bioavailable without needing the elaborate delivery systems that oral semaglutide (Rybelsus) requires.

Once bound to the GLP-1 receptor, danuglipron activates the same downstream signaling pathways as natural GLP-1: it increases insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite and food intake by acting on receptors in the brain.

Clinical Development Timeline

Danuglipron moved through clinical development at a notable pace:

Phase 1 (2021): A randomized, placebo-controlled multiple ascending-dose trial established basic pharmacokinetics, safety, and early efficacy signals in type 2 diabetes patients.
Phase 2a: A randomized clinical trial published in JAMA Network Open demonstrated HbA1c reductions of up to 1.2% with twice-daily dosing, establishing proof-of-concept for glycemic control.
Phase 2b Obesity Trial (2023-2024): The pivotal obesity trial testing danuglipron at doses from 40 mg to 200 mg twice daily over 32 weeks.
Dose Optimization Studies (2024-2025): Pfizer shifted to a modified-release once-daily formulation to improve tolerability.
Discontinuation (April 14, 2025): Pfizer announced the end of all danuglipron clinical development.

Phase 2b Results: What the Weight Loss Data Actually Showed

The Phase 2b trial results told a complicated story. On efficacy, danuglipron clearly worked. On tolerability, it clearly didn't — at least not well enough to sustain a viable patient population.

Efficacy: Significant Weight Loss Across All Doses

At 32 weeks, all danuglipron dose groups achieved statistically significant and clinically meaningful weight reductions compared to placebo. Placebo-adjusted weight loss ranged from approximately -8% to -13% depending on dose. In absolute terms, participants in the highest dose arms lost roughly 10-13% of their body weight from baseline — figures that, on paper, compete with early injectable GLP-1 data.

The least squares mean percentage decreases from baseline ranged from -5.0% to -12.9% relative to placebo across the dose range, with higher doses producing greater but less tolerable weight loss.

The Tolerability Crisis: Why More Than 60% Dropped Out

Of the 626 participants who received study treatment in the Phase 2b obesity trial, only 39.3% completed the full 32-week treatment period. More than 38% of participants discontinued specifically due to adverse events, with GI side effects — nausea, vomiting, diarrhea — as the primary culprit. An additional 22% dropped out for other reasons.

This created a painful dose-response trap: the doses producing the best weight loss also produced the most intolerable side effects. For context, injectable semaglutide trials in the STEP program saw completion rates above 85%. Danuglipron's 39% completion rate signaled that twice-daily dosing at effective concentrations was simply not patient-friendly enough for a chronic obesity medication.

Pfizer's Attempted Fix: The Once-Daily Modified-Release Formulation

Pfizer didn't abandon danuglipron after the Phase 2b tolerability data. Instead, the team invested in a modified-release (MR) once-daily formulation, hypothesizing that smoother drug release could reduce the peak plasma concentrations responsible for the worst GI effects.

In 2024, Pfizer selected this once-daily MR formulation for further development after dose-optimization studies met key pharmacokinetic objectives. The data appeared to confirm a dose with the potential to deliver competitive efficacy and an improved tolerability profile — Phase 3 testing seemed within reach.

Then came the liver signal.

The Liver Injury Signal That Ended the Program

During dose-optimization studies of the once-daily formulation in early 2025, a single participant experienced what Pfizer characterized as potential drug-induced liver injury (DILI). Critically, the case was asymptomatic — no symptoms, and liver enzymes recovered rapidly after stopping danuglipron.

A single asymptomatic case in a dose-optimization study might seem like a manageable signal in other therapeutic areas. But in obesity treatment — where the drug is taken by otherwise healthy individuals, and where regulatory standards for safety are exceptionally high — even one potential DILI case is taken extremely seriously.

Pfizer reviewed all liver enzyme data across the complete danuglipron clinical program. The company noted that the overall frequency of liver enzyme elevations was broadly consistent with what has been reported for other approved GLP-1 agents. Nevertheless, after incorporating feedback from regulatory authorities and reviewing the totality of the safety and efficacy profile, Pfizer concluded that further development could not be justified.

On April 14, 2025, Pfizer formally discontinued the danuglipron clinical development program for chronic weight management.

Danuglipron vs. Orforglipron: The Oral GLP-1 Race

Danuglipron's discontinuation substantially clarifies the competitive landscape. Its closest scientific analog — and now the leading oral small-molecule GLP-1 — is Eli Lilly's orforglipron.

Both are non-peptide, small-molecule GLP-1 receptor agonists designed for once-daily oral dosing without food restrictions. But their development trajectories have diverged sharply:

Tolerability: Orforglipron's once-daily dosing appears to produce GI side effects at rates more manageable than danuglipron's BID profile, with considerably higher trial completion rates.
Efficacy: Phase 3 ACHIEVE program data released in 2026 showed orforglipron was superior to oral semaglutide in HbA1c reduction in type 2 diabetes over 52 weeks — a significant milestone.
Safety: Orforglipron has not generated concerning liver enzyme signals to date, a critical advantage given what ended danuglipron's program.

The key differentiator: orforglipron found a dose range that balances efficacy and tolerability without the safety flags that derailed danuglipron. With Lilly's manufacturing scale and strong regulatory track record with tirzepatide, orforglipron is now viewed as the most likely first oral small-molecule GLP-1 to reach broad clinical use.

Danuglipron vs. Injectable GLP-1s: The Efficacy Gap

To put danuglipron's weight loss numbers in market context:

Semaglutide 2.4 mg (Wegovy): Approximately 15% weight loss at 68 weeks
Tirzepatide (Zepbound): Approximately 20-22% weight loss at 72 weeks
Oral semaglutide (Rybelsus): Approximately 3-5% weight loss in obesity studies
Danuglipron BID (Phase 2b): Approximately 8-13% placebo-adjusted at 32 weeks

On duration-adjusted terms, danuglipron's efficacy trajectory was competitive with first-generation injectable semaglutide. The fundamental problem was never efficacy — it was getting patients to stay on the drug long enough to realize those benefits. The 60%+ dropout rate meant the impressive weight loss numbers were coming from a survivor population that could tolerate the drug, not a representative sample of patients with obesity.

What Pfizer's Exit Means for the Oral GLP-1 Market in 2026

Danuglipron's discontinuation is a significant event in the oral GLP-1 story, but not the end of it. The demand for an oral weight loss medication remains massive and largely unmet. Tens of millions of patients who could benefit from GLP-1 therapy are deterred by weekly injections, needle phobia, cold-chain logistics, or simple personal preference.

What danuglipron's failure teaches the field:

Twice-daily dosing is likely a dead end for oral GLP-1s. Peak plasma concentrations from BID small molecules create compounding GI burden. Once-daily modified-release formulations are the appropriate path forward.
Liver safety monitoring must be embedded in early trials. A single DILI signal is enough to terminate a program. Companies must build extensive liver safety databases before entering Phase 3 obesity trials.
The efficacy bar has risen dramatically. With tirzepatide achieving ~20% weight loss and retatrutide showing even higher in early trials, any new oral GLP-1 needs to demonstrate not just statistical significance but clinically competitive efficacy.

As of 2026, orforglipron remains the most advanced oral small-molecule GLP-1 alternative. Several other pharmaceutical companies — including AstraZeneca and Novo Nordisk — continue developing oral GLP-1 candidates at various stages. The race continues; danuglipron simply didn't finish it.

Key Takeaways

Discontinued April 14, 2025 after a potential DILI signal in a single asymptomatic patient
Phase 2b showed genuine efficacy: -8% to -13% placebo-adjusted weight loss at 32 weeks
GI tolerability was the persistent problem: over 60% dropout rates, primarily from nausea and vomiting
Twice-daily dosing was the core tolerability issue; once-daily MR was being developed when the liver signal emerged
Orforglipron (Eli Lilly) is now the leading oral small-molecule GLP-1 candidate
The science of oral GLP-1s remains sound — danuglipron's failure was safety and tolerability execution, not a failure of the underlying concept

Conclusion

Danuglipron's story is both a cautionary tale and a scientific progress report. Pfizer had a mechanistically novel, orally available GLP-1 receptor agonist with real Phase 2b efficacy data in a patient population desperately seeking alternatives to injections. The program ended not because the science was wrong, but because the clinical execution — tolerability, formulation, and ultimately one liver safety signal — couldn't clear the high bar regulators and patients rightfully require.

For patients seeking oral GLP-1 options in 2026, danuglipron is no longer a possibility. But the knowledge it generated — about small-molecule GLP-1 binding, oral bioavailability, dose-response relationships, and the tolerability challenges of BID dosing — directly informs the next generation of candidates now advancing through clinical trials.

The oral GLP-1 pill remains one of the most consequential pharmaceutical challenges of this decade. Danuglipron didn't cross the finish line. The race, however, continues.